GENELUX Corp
No enriched coverage for $GNLX in the last 7 days.
GENELUX Corp (GNLX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001231457 0001231457 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
Smalling Ralph (Head of Regulatory) sold 192 shares of GENELUX Corp (GNLX) at $2.93 on 2026-06-03.
Thomas John sold 10,000 shares of GENELUX Corp (GNLX) at $2.98 on 2026-06-01 under a Rule 10b5-1 trading plan.
Recent GNLX coverage spans financial news, insider activity and corporate actions.
In the last 30 days, GNLX insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($13K). The most active reporter was Yu Yong, Chief Scientific Officer, with 1 filing.
Routine shareholder-meeting outcomes; limited direct implications beyond governance/audit confirmation.
An insider sale disclosed via Form 4 is typically low-signal for fundamentals, but can slightly affect near-term sentiment.
Insider selling disclosed via Form 4; likely limited fundamental signal given pre-arranged 10b5-1, but can affect near-term sentiment/flow.
The insider selling by Yu Yong, SVP of Genelux, coincides with a significant share price decline and weak financial health, indicating potential negative sentiment.
The sale of 585 shares by the Head of Regulatory is likely a personal liquidity event to cover RSU taxes. This does not inherently signal negative or positive company prospects.
alphai scores every news story that mentions GNLX with an AI model for sentiment and relevance, and aggregates insider trades from GENELUX Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
GENELUX Corp (GNLX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001231457 0001231457 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readSmalling Ralph (Head of Regulatory) sold 192 shares of GENELUX Corp (GNLX) at $2.93 on 2026-06-03.
2 min readThomas John sold 10,000 shares of GENELUX Corp (GNLX) at $2.98 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readYu Yong, SVP of Clinical Development at Genelux Corp (NASDAQ:GNLX), sold 906 shares for $2.42 each, totaling $2192, to cover taxes on restricted stock units. This transaction occurred amidst a 39% year-to-date decline in GNLX shares, which are near their 52-week low. The company, with a market cap of $117.59 million, has a "WEAK" financial health score and is burning cash quickly.
3 min readGenelux (GNLX) Head of Regulatory, Ralph Smalling, sold a total of 585 shares of common stock on March 24 and 25, 2026, at prices between $2.42 and $2.51 per share. These transactions were made to cover estimated taxes related to vesting restricted stock units. Following these sales, Smalling's direct holdings in GENELUX common stock amount to 68,073 shares.
2 min readGenelux Corporation announced the pricing of an underwritten public offering of common stock, aiming to raise $20 million. The company plans to sell 6,666,667 shares at $3.00 each, with the offering expected to close on January 9, 2026. The proceeds are intended for general corporate purposes, including research and development.
3 min readGenelux Corp (NASDAQ:GNLX) stock dropped 10.3% in after-hours trading following the announcement of a proposed underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of shares, with Lucid Capital Markets acting as the sole book-running manager. Genelux, a clinical-stage immuno-oncology company, did not disclose the terms or size of the offering, which is subject to market conditions.
4 min readWESTLAKE VILLAGE, Calif., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Genelux Corporation ( NASDAQ: GNLX ) , a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will participate in a ...
2 min read-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of ...
3 min readWESTLAKE VILLAGE, Calif., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Genelux Corporation ( NASDAQ: GNLX ) , a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates.
3 min read
